Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nextbiomedical Co's total inventories for the quarter that ended in Jun. 2026 was ₩3,059 Mil. Nextbiomedical Co's average total inventories from the quarter that ended in Mar. 2026 to the quarter that ended in Jun. 2026 was ₩2,964 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Nextbiomedical Co's Net-Net Working Capital per share for the quarter that ended in Jun. 2026 was ₩3,067.80.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Nextbiomedical Co's Days Inventory for the
three
months ended in Jun. 2026 was 190.45.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Nextbiomedical Co's Inventory Turnover for the quarter that ended in Jun. 2026 was 0.48.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Nextbiomedical Co's Inventory-to-Revenue for the quarter that ended in Jun. 2026 was 0.60.
Nextbiomedical Co (XKRX:389650) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Nextbiomedical Co's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Nextbiomedical Co's Inventory to Revenue for the quarter that ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Nextbiomedical Co Total Inventories Related Terms
Nextbiomedical Co Total Inventories Historical Data
* Premium members only.
The historical data trend for Nextbiomedical Co's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Nextbiomedical Co (XKRX:389650) has a Total Inventories of ₩3,059 Mil as of Jun. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for Nextbiomedical Co and its competitors.
Is Nextbiomedical Co's Total Inventories too high?
Nextbiomedical Co's current Total Inventories is ₩3,059 Mil. Overall, Nextbiomedical Co has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Nextbiomedical Co's Total Inventories compare to VRTX and REGN?
Nextbiomedical Co's Total Inventories of ₩3,059 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Nextbiomedical Co and its competitors. Nextbiomedical Co's current Total Inventories is ₩3,059 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nextbiomedical Co stock overvalued right now?
Nextbiomedical Co (XKRX:389650) has a current Total Inventories of ₩3,059 Mil. The current Total Inventories is ₩3,059 Mil. Nextbiomedical Co's overall GF Score™ is 38/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Nextbiomedical Co (XKRX:389650), the current Total Inventories is ₩3,059 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nextbiomedical Co Ltd is an bio-solution company. The company develops and commercializes therapeutic agents for treating diseases based on polymer and drug delivery system technology. The company has developed products that include endoscopic hemostatic agents, vascular embolic microspheres, and others.
38GF Score
Get the complete analysis for XKRX:389650
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKRX:389650 has been successfully added to your 
